Selti - Flywheelsites News
However, clinical evidence on treatment effects of egfr targeted therapies such as afatinib in nrg1 fusion-positive lung cancer is limited due to relatively low frequency of nrg1 fusions. The fda approved the targeted therapy zenocutuzumab-zbco for certain patients with lung or pancreatic cancer with nrg1 gene fusions. A substantial proportion (≈20%) of nrg1 fusion-positive non-small-cell lung cancer (nsclc) cases are non-mucinous adenocarcinomas.
